Abstract #0126

Chemotherapeutic drugs profoundly alter the metabolism of triple negative breast cancer cells

Kanchan Sonkar¹, Caitlin M. Tressler¹, and Kristine Glunde^1,2

¹The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States, ²The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Triple negative breast cancer (TNBC) is a highly aggressive form of cancer that poses severe health care problem as no targeted therapeutics are available for its treatment. TNBC is treated with chemotherapeutic agents, including doxorubicin, paclitaxel, vinorelbine, 5-fluorouracil, melphalan and cisplatin , which are either used alone or in various combinations. Studies investigating the metabolic effects of chemotherapy in TNBC are still limited. Here we have used high-resolution ¹H MRS to study the metabolic profiles of TNBC cell lines MDA-MB-231 and SUM159 treated with these chemotherapeutic agents as compared to untreated controls.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.